AI Defense Stock VisionWave Holdings, Inc. (Nasdaq: $VWAV) Update on Discussions for Strategic Opportunities in Indian Defense Modernization; @VWAVInc

 

AI Defense Stock VisionWave Holdings, Inc. (Nasdaq: $VWAV) Update on Discussions for Strategic Opportunities in Indian Defense Modernization; @VWAVInc

 

 

West Hollywood, California August 21 2025 –  ( Investorideas.com Newswire)  Breaking Defense Stock News -VisionWave Holdings, Inc. (Nasdaq: VWAV), a U.S.-based defense technology company specializing in advanced imaging, autonomous systems, and its proprietary Evolved Intelligence (EI) powered threat detection, today announced meaningful progress in its engagement with India’s evolving defense modernization landscape.

 

The Company has initiated exploratory discussions with leading defense entities and system integrators in India with the goal of obtaining multi-year procurement and battlefield technology upgrade programs.

 

According to SIPRI 2024 and India’s latest Union Budget 2025-26, India represents one of the world’s largest and fastest-growing defense markets, with annual expenditures exceeding $80 billion and modernization initiatives projected at more than $250 billion this decade. VisionWave believes its platform and EI core technologies, which is built around real-time autonomous threat detection, super-resolution radar, and advanced sensor fusion, are strongly aligned with India’s strategic goals of enhancing armored mobility, force survivability, and indigenous defense capabilities as part of its next-generation active protection and counter-UAS solutions.

 

Paid News Dissemination on behalf of VWAV

 

Read this news featuring VWAV in full at: https://www.investorideas.com/co/bnix/news/2025/08211VisionWave-India-Defense-Update.asp

 

The opportunities under discussion are aligned with armored fleet upgrades and innovation initiatives and include:

·        Integration of VisionWave’s modular counter-UAS solutions and proprietary detection systems into next-generation armored platforms, delivered as part of the VisionWave Tactical Active Protection System (T-APS);

·        Participation in demonstration trials of counter-UAS solutions with integrated detection systems under India’s battlefield innovation initiatives;

·        Retrofitting VisionWave’s Tactical Active Protection System (T-APS) to strengthen force protection and survivability across legacy armored fleets.

 

To support these initiatives, VisionWave has executed a mutual non-disclosure agreement with a domestic Indian defense partner and is in advanced discussions seeking to enter into a memorandum of understanding (MoU) to govern future collaboration. In parallel with its ongoing live-fire trial program in Abu Dhabi, which is scheduled for September 2025, VisionWave is evaluating the feasibility of a similar live demonstration in India, subject to regulatory coordination and program readiness.

 

“India is a strategically important market for VisionWave, and we are committed to supporting its defense innovation objectives with our scalable, proprietary, EI-driven technologies,” said Noam Kenig, CEO of VisionWave. “We see growing demand for Active Protection Systems, counter-UAS capabilities, the elimination of incoming threats, and real-time sensing — all areas where VisionWave maintains a clear technological edge.”

 

This initiative directly aligns with VisionWave’s previously disclosed strategic roadmap. As noted in the Company’s most recent SEC filings:

 

“The Indian Ministry of Defense is working with Target to install and deploy its solutions along India’s borders. This engagement is structured as a 10-year agreement to provide Target’s solutions and ongoing services. As part of this initiative, Target anticipates establishing manufacturing facilities in India, enabling a substantial long-term partnership and large-scale deployment.”

(Source: SEC filing, VisionWave S-4/A Prospectus, Page 170)

 

VisionWave remains committed to advancing international partnerships that align with its mission to deliver dependable, real-time, and life-saving technologies to defense and security forces worldwide.

 

About VisionWave Holdings Inc.

VisionWave Holdings Inc. (Nasdaq: VWAV) is a U.S.-based defense technology company advancing next-generation battlefield capabilities through EI-powered sensing platforms and autonomous defense systems. Leveraging proprietary super-resolution radar, multispectral, and radio-frequency imaging technologies, VisionWave provides real-time threat detection, enhanced force survivability, and superior decision-making across air, land, and sea domains.

 

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the estimated implied enterprise value of the Combined Company, VisionWave Holdings’ ability to scale and grow its business, the advantages and expected growth of the Combined Company, the Combined Company’s ability to source and retain talent, and the cash position of the Combined Company following closing of the Business Combination, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of VisionWave Technologies’ management and are not predictions of actual performance.

 

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each of BNIX, VisionWave Technologies and VisionWave Holdings believes that it has a reasonable basis for each forward-looking statement contained in this press release, each of BNIX, VisionWave Technologies and VisionWave Holdings cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the definitive proxy statement/prospectus mailed to BNIX stockholders, and filed by the Combined Company with the SEC and other documents filed by the Combined Company or BNIX from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. BNIX, VisionWave Technologies and VisionWave Holdings cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the Business Combination, the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination, the outcome of any potential litigation, government or regulatory proceedings, and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the definitive proxy statement/prospectus mailed to BNIX stockholders, and those included under the heading “Risk Factors” in the annual report on Form 10-K for the fiscal year ended December 31, 2024, of BNIX and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional risks that BNIX, VisionWave Technologies and VisionWave Holdings presently do not know or that the parties currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of BNIX, VisionWave Technologies and VisionWave Holdings as of the date of this press release. Subsequent events and developments may cause those views to change. However, while BNIX, VisionWave Technologies and VisionWave Holdings may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of BNIX, VisionWave Technologies and VisionWave Holdings as of any date subsequent to the date of this press release. Except as may be required by law, BNIX, VisionWave Technologies and VisionWave Holdings do not undertake any duty to update these forward-looking statements.

 

For more information, visit: www.vwav.inc

Investor Contact:
investors@vwav.inc

 

VisionWave is a Featured Defense stock on Investorideas.com

https://www.investorideas.com/CO/BNIX/

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid featured defense company on Investorideas.com. Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Follow & Contact

Follow us on X: @investorideas   @stocknewsbites

Facebook: https://www.facebook.com/Investorideas

YouTube: https://www.youtube.com/c/Investorideas

 

 

Get more defense aerospace stock investing ideas with Investorideas.com free stock directory

 

Defense AI Stock VisionWave (NASDAQ: $VWAV) Announces two intellectual property updates; Radio Wave Finder technology and Evolved Intelligence™ (EI) @VWAVInc

 

Defense AI Stock VisionWave  (NASDAQ: $VWAV) Announces two intellectual property updates; Radio Wave Finder technology and Evolved Intelligence™ (EI) @VWAVInc

 

 

 

WEST HOLLYWOOD, Calif., August 19, 2025 – ( Investorideas.com Newswire) Breaking Defense stock news- VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a defense technology company specializing in AI-powered sensing and autonomous threat-response systems, today announced two intellectual property updates that seek to strengthen its technology and intellectual property strategy. VisionWave has accelerated prosecution of a continuation patent related to its Radio Wave Finder technology.  Further, VisionWave is introducing Evolved Intelligence™ (EI), VisionWave’s real-time, embedded AI engine designed for defense-grade autonomy at the edge.

 

Paid News Dissemination on behalf of VWAV

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/BNIX/news/2025/08191visionwave-defense-ai-radio-wave-finder-evolved-intelligence.asp

 

USPTO update - Radio Wave Finder continuation

On August 12, 2025, the U.S. Patent and Trademark Office (“USPTO”) issued a first Office Action on the Company’s continuation application. The Office Action raised a procedural double-patenting matter that can be addressed via a Terminal Disclaimer; no other substantive issues were identified. VisionWave filed its formal response - including a Terminal Disclaimer - on August 18, 2025, to help expedite examination. The Company filed its response six days after the Office Action, demonstrating timely attention to IP matters. Patent issuance is not guaranteed until granted by the USPTO. The continuation describes a multi-planar radio-wave detection and imaging system with an AI analysis component for use across air, water, ground, and space domains.

 

Technology Momentum - Evolved Intelligence™ (EI)

EI is VisionWave’s real-time, embedded AI engine engineered for split-second, on-device decision-making in contested or bandwidth-limited environments. Its modular architecture combines multi-modal sensor fusion with a deterministic, edge-optimized runtime to deliver low-latency perception, prediction, and control across drones, unmanned ground vehicles, guided munitions, sensors and humanoid robotics. EI is intended to serve as a common autonomy layer across sensors and platforms.  Separately, VisionWave has filed a U.S. trademark application for EVOLVED INTELLIGENCE™ (Serial No. 99317884); registration is not guaranteed and remains subject to standard USPTO examination.

 

Management commentary

Noam Kenig, Chief Executive Officer, VisionWave said “EI is designed to combine logic- and data-driven models with an added reasoning layer, with the goal of enabling more context-aware decision support in real time.” Mr. Kenig continued “our RF-to-image sensing approach is being developed to improve range and reduce clutter in contested environments.”

“EI is built for deterministic, low-latency decisions at the edge. Our patent-pending multi-planar RF-to-image sensing architecture synchronizes phased arrays with on-device inference to reconstruct high-fidelity target signatures from sparse emissions - cutting clutter and boosting range and precision. Coupled with EI’s fusion layer, it is being developed with the goal of improving range and precision in contested EW environments” added, Dr. Danny Rittman, Chief Technology Officer, VisionWave.

 

Recent U.S. government initiatives and semiconductor programs underscore broader demand trends for edge-based autonomy. While VisionWave’s technologies may be applicable in these areas, the Company has not entered into agreements under such programs. VisionWave’s recent IP filings reflect an ongoing strategy to strengthen protection of its inventions and related brand assets.

 

Below is a summary of VisionWave EI offering:

·        Deterministic edge autonomy: bounded-latency inference and control for mission-critical timing.

·        Multi-modal fusion: radar/RF/EO/IR/system-health unified into a coherent operating picture.

·        Patent-pending RF-to-image sensing: multi-planar architecture designed to reduce clutter and enhance range/precision.

·        Scalable runtime: modular, hardware-agnostic deployment across air, land, sea, and stationary sensors.

·        IP + TM protection: expanding patent estate plus the EVOLVED INTELLIGENCE™ trademark to protect the technology and brand assets.

·        Program-ready posture: designed for comms-denied/GPS-denied operations and export-control-aware integrations.

 

Trademark Notice

EVOLVED INTELLIGENCE™ is a trademark of VisionWave Holdings, Inc. U.S. trademark registration is pending and not guaranteed.

 

About VisionWave Holdings, Inc.

VisionWave Holdings Inc. (Nasdaq: VWAV) is a U.S.-based defense technology company advancing next-generation battlefield capabilities through AI-powered sensing platforms and autonomous defense systems. Leveraging proprietary super-resolution radar, multispectral, and radio-frequency imaging technologies, VisionWave provides real-time threat detection and decision-support capabilities across air, land, and sea domains. The Company is incorporated in Wilmington, Delaware, with its operational headquarters in West Hollywood, California, and maintains advanced research and development operations in Canada.

 

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the estimated implied enterprise value of the Combined Company, VisionWave Holdings' ability to scale and grow its business, the advantages and expected growth of the Combined Company, the Combined Company's ability to source and retain talent, and the cash position of the Combined Company following closing of the Business Combination, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of VisionWave Technologies' management and are not predictions of actual performance.

 

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although each of BNIX, VisionWave Technologies and VisionWave Holdings believes that it has a reasonable basis for each forward-looking statement contained in this press release, each of BNIX, VisionWave Technologies and VisionWave Holdings cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the definitive proxy statement/prospectus mailed to BNIX stockholders, and filed by the Combined Company with the SEC and other documents filed by the Combined Company or BNIX from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. BNIX, VisionWave Technologies and VisionWave Holdings cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the Business Combination, the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination, the outcome of any potential litigation, government or regulatory proceedings, and other risks and uncertainties, including those to be included under the heading "Risk Factors" in the definitive proxy statement/prospectus mailed to BNIX stockholders, and those included under the heading "Risk Factors" in the annual report on Form 10-K for the fiscal year ended December 31, 2024, of BNIX and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional risks that BNIX, VisionWave Technologies and VisionWave Holdings presently do not know or that the parties currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of BNIX, VisionWave Technologies and VisionWave Holdings as of the date of this press release.

 

Subsequent events and developments may cause those views to change. However, while BNIX, VisionWave Technologies and VisionWave Holdings may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of BNIX, VisionWave Technologies and VisionWave Holdings as of any date subsequent to the date of this press release. Except as may be required by law, BNIX, VisionWave Technologies and VisionWave Holdings do not undertake any duty to update these forward-looking statements.

 

For more information, visit: www.vwav.inc

Investor Contact: investors@vwav.inc 

 

VisionWave is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/BNIX/

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Follow & Contact

Follow us on X: @investorideas   @stocknewsbites

Facebook: https://www.facebook.com/Investorideas

YouTube: https://www.youtube.com/c/Investorideas

 

 

Get more defense aerospace stock investing ideas with Investorideas.com free stock directory

 

Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Fiscal First Quarter Results Ending June 30, 2025, and Corporate Update

 

Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Fiscal First Quarter Results Ending June 30, 2025, and Corporate Update

 

Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32%

 

Conference Call to be Held Today at 4:30 p.m. ET

 

SAN DIEGO, Aug. 13, 2025 /( Investorideas.com Newswire)  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments. 

 

Key First Quarter Highlights

·  First Cohort Complete in Australian Hemopurifier® cancer trial — all patients treated without device-related serious adverse events and no dose-limiting toxicities observed

·  Amended Protocol broadens patient eligibility to allow all treatment regimens that include an anti-PD-1 agent

·  Preclinical Data: 98.5% removal of platelet-derived extracellular vesicles (EVs) in simulated 4-hour treatment

·  Long COVID Pre-Clinical Research collaboration with UCSF advances, with findings presented at the prestigious Keystone Symposium

·  Operating Expenses Reduced by 31.6%, enhancing operational efficiency

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2025/08131aethlon-medical-aemd-q1-2025-financial-results-conference-call.asp

 

Clinical Progress in Cancer Trial

Ongoing progress continues in the Australian Oncology trial evaluating the Hemopurifier in participants with solid tumors that have not responded to anti-PD-1 immunotherapy.

Aethlon successfully completed the first treatment cohort in its safety, feasibility, and dose-finding study. This initial cohort involved single Hemopurifier treatments for participants with tumors unresponsive to PD-1 inhibitors such as pembrolizumab (Keytruda®) or nivolumab (Opdivo®). Treatments were completed at Royal Adelaide Hospital and Royal North Shore Hospital between late January and June 2025. All participants tolerated the 4-hour Hemopurifier treatment without device-related deficiencies or immediate complications, and no dose-limiting toxicities or device-related serious adverse events were observed at the pre-specified 7-day safety follow-up. One participant subsequently died from disease progression, unrelated to the Hemopurifier treatment, and was only able to complete one week of follow-up.

 

On July 11, 2025, the independent Data Safety Monitoring Board (DSMB) convened to review the safety data from the three participants in this first cohort. Following closed-session deliberations, the DSMB recommended advancing to the second treatment cohort, in which participants will receive two Hemopurifier treatments within a one-week period.

All three clinical sites in Australia are actively screening patients for the cohort two under an amended protocol. The amendment expands eligibility to patients receiving either monotherapy or combination therapy that includes Pembrolizumab or Nivolumab, better reflecting current standards of care and broadening the potential patient pool.

Meanwhile, Professor Georges Grau's laboratory at the University of Sydney continues to analyze central lab samples from the first patient cohort to assess the effects of the Hemopurifier on extracellular vesicle counts and anti-tumor T cell activity. Initial observations from this analysis are expected in September 2025.

 

As a reminder, the primary endpoint of the approximate 9 to 18-participant trial is safety. Eligible patients with solid tumors with stable or progressive disease receive escalating doses of Hemopurifier treatment across sequential cohorts - one, two, and three Hemopurifier treatments administered over the course of a single week. In addition to evaluating safety, the study is designed to assess whether reducing the concentration of extracellular vesicles (EVs) may improve the body's own natural ability to attack tumor cells. These exploratory findings are expected to inform the design of future efficacy and safety trials, including a Premarket Approval (PMA) study.

 

We believe the unmet need remains significant: currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors are believed to contribute to both cancer progression and resistance to anti-PD-1 therapies. The Hemopurifier, designed to selectively bind and remove EVs from the bloodstream, has demonstrated EV reduction in preclinical studies using plasma from cancer patients, and may improve therapeutic response rates to anti-PD-1 antibodies.

 

India Update

While the Company received formal approval from India's Central Drugs Standard Control Organization (CDSCO) to initiate a similar oncology trial at Medanta Medicity Hospital, subsequent timeline discussions with our India-based CRO indicated the first patient treatment would likely not occur until the beginning of 2026. Given this extended timeline and with careful consideration of both projected costs and our broader strategic priorities, we made the decision not to proceed with the India study. We believe this allows us to focus our resources on advancing our ongoing trial in Australia, which remains better aligned with our goal of generating timely clinical data to support a potential PMA trial.

 

Preclinical Study Supports Broader Applications

On May 12, 2025, results from Aethlon's preclinical ex vivo study were published in bioRxiv, with a manuscript now under review at a peer-reviewed journal. The study showed that the Hemopurifier, utilizing Aethlon's proprietary Galanthus nivalis agglutin (GNA) affinity resin, removed 98.5% of platelet -derived extracellular vesicles (PD-EVs) from healthy human plasma during a timepoint equivalent to a 4-hour HP treatment. Excessive levels of PD-EVs have been associated with a wide range of conditions, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, and acute and Long COVID. We believe these findings support the scientific rationale behind Aethlon's ongoing oncology trial in Australia and suggest broader potential applications of the Hemopurifier in other EV-associated diseases.

 

Scientific Collaboration in Long COVID Research

On August 12th, 2025, Aethlon presented a poster at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes held in Santa Fe, New Mexico. Long COVID, characterized by persistent symptoms following acute COVID-19 infection, affect approximately 44 and 48 million people in the United States alone with an estimated economic burden of 2 billion dollars among those with symptoms lasting a year. Despite the scope of this public health challenge, no specific treatments are currently available, highlighting a significant unmet medical need.

 

EVs have been implicated in the pathogenesis of Long COVID. Building on prior evidence that the Aethlon Hemopurifier can remove EVs in a patient with severe acute COVID-19 infection, the Company hypothesized EVs from individuals with Long COVID may also express surface mannose sugar that binds to its proprietary GNA. Aethlon partnered with investigators at the University of California San Francisco Medical Center Long COVID clinic to obtain samples from participants with Long COVID as well recovered COVID -19 participants as controls.

 

The data presented at the symposium demonstrated that both large and small EVs from Long COVID patients bound to the GNA lectin and the Hemopurifier's lectin affinity resin, supporting the potential utility of the device in affected individuals.

 

The full poster will soon be available for public viewing on the Aethlon Medical website.

 

Operational Achievements

"In the first quarter, we advanced our lead oncology program, delivered preclinical results supporting broader applications including Long COVID — all while significantly reducing operating expenses," said James Frakes, Chief Executive Officer of Aethlon Medical. "We remain committed to driving the Hemopurifier toward regulatory approval and unlocking its potential across multiple disease areas."

 

Financial Results for the Fiscal First Quarter Ended June 30, 2025

As of June 30, 2025, Aethlon had a cash balance of approximately $3.8 million.

 

For the three months ended June 30, 2025, consolidated operating expenses were approximately $1.8 million, representing a decrease of approximately $800,000 or approximately 31.6%, compared to approximately $2.6 million for the same period in 2024. This reduction was primarily driven by lower payroll and related expenses, professional fees, and general and administrative costs.

 

Payroll and related expenses declined by approximately $674,000, largely due to the absence of a $321,000 in severance expense recorded in the prior-year quarter related to the separation of an executive. In addition, the Company realized a $286,000 reduction in compensation costs as a result of lower headcount, as well as a $67,000 decrease in stock-based compensation tied to the same reduction in the workforce.

 

Professional fees decreased by an approximate $138,000, primarily due to a $104,000 reduction in legal fees following the transition to a new legal firm, a $34,000 decrease in scientific consulting costs after the conclusion of a project, a $23,000 reduction in audit-related fees. Additionally contract labor costs decreased by $18,000 due to the completion of a regulatory project and shift to lower-cost quality management system consultants. These reductions were partially offset by a $42,000 increase in investor relations expenses related to the special meeting of stockholders held during the quarter.

 

General and administrative expenses declined by an approximate $17,000, primarily driven by a $31,000 reduction in insurance costs, partially offset by a $26,000 increase in clinical trial-related expenses. Other variances included a mix of increases and decreases across multiple categories, none of which were individually significant, resulting in an overall decline.

 

As a result of the above factors, operating loss for the quarter decreased to $1.8 million compared to $2.6 million for the three months ended June 30, 2024.

 

Other Income

Other income totaled $30,532 for the three months ended June 30, 2025, compared to $49,418 in the prior-year period. In both quarters, other income was primarily interest income earned on cash balances.

 

The consolidated balance sheets for June 30, 2025 and March 31, 2025, along with the consolidated statements of operations for the three months ended June 30, 2025 and 2024, are included at the end of this release.

 

Conference Call

Management will host a conference call today, Wednesday, August 13, 2025, at 4:30 p.m. ET to review the company's financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

 

Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10201884/ffac7acee8. Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

PARTICIPANT DIAL IN (TOLL-FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through September 13, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll-free at 1-855-669-9658. The replay conference ID number is 1454680.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

 

About Aethlon Medical, Inc.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

 

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
Unaudited
ASSETS
			June 30, 2025		March 31, 2025
CURRENT ASSETS
	Cash and cash equivalents		$                       3,765,154		$                                 5,501,261
	Deferred offering costs		9,103		-
	Prepaid expenses and other current assets		276,601		448,539
TOTAL CURRENT ASSETS			4,050,858		5,949,800
	Property and equipment, net		593,720		676,220
	Operating lease right-of-use asset		529,576		601,846
	Patents, net		413		550
	Restricted cash		98,130		97,813
	Deposits		33,305		33,305
TOTAL ASSETS			$                   5,306,002		$                           7,359,534
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
	Accounts payable		$                          571,495		$                                    534,524
	Due to related parties		372,598		579,565
	Operating lease liability, current portion		318,800		313,033
	Other current liabilities		364,544		472,164
TOTAL CURRENT LIABILITIES			1,627,437		1,899,286
	Operating lease liability, less current portion		255,052		336,718
TOTAL LIABILITIES			1,882,489		2,236,004
STOCKHOLDERS' EQUITY
	Common stock, $0.001 par value; 60,000,000 shares authorized as of June 30, 2025 and March 31, 2025; 2,598,711 and 2,585,239 shares issued and 2,598,711 and 2,010,739 outstanding as of June 30, 2025 and March 31, 2025, respectively		2,599		2,586
	Additional paid-in capital		173,159,966		173,092,894
	Accumulated other comprehensive loss		(22,377)		(17,133)
	Accumulated deficit		(169,716,675)		(167,954,817)
TOTAL STOCKHOLDERS' EQUITY			3,423,513		5,123,530
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY			$                   5,306,002		$                           7,359,534

 

AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
For the three months ended June 30, 2025 and 2024
Unaudited
		Three Months		Three Months
		Ended 6/30/25		Ended 6/30/24
OPERATING EXPENSES
Professional fees		$          476,032		$          614,082
Payroll and related expenses		581,000		1,254,802
General and administrative		735,358		751,974
Total operating expenses		1,792,390		2,620,858
OPERATING LOSS		(1,792,390)		(2,620,858)
OTHER (EXPENSE) INCOME, NET
Interest income		36,466		49,418
Other expense		(5,934)		-
Total other expense (income)		30,532		49,418
NET LOSS		(1,761,858)		(2,571,440)
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.		(1,761,858)		(2,571,440)
OTHER COMPREHENSIVE LOSS		(5,244)		(833)
COMPREHENSIVE LOSS		$     (1,767,102)		$     (2,572,273)
Basic and diluted net loss per share attributable to common stockholders		$              (0.85)		$              (2.76)
Weighted average number of common shares outstanding - basic and diluted		2,076,416		932,248

 

 

More info on AEMD at Investorideas.com

 

Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Get more biotech and medical tech news, articles, podcasts and stock directories